Document is current
Any future updates will be listed below
-
Authors
Orsi, Emanuela
Solini, Anna
Penno, Giuseppe
Bonora, Enzo
Fondelli, Cecilia
Trevisan, Roberto
Vedovato, Monica
Cavalot, Franco
Lamacchia, Olga
Haxhi, Jonida
Nicolucci, Antonio
Pugliese, Giuseppe
,
Laviola, Luigi
Bollanti, Lucilla
Alessi, Elena
Vitale, Martina
Cirrito, Tiziana
Cavallo-Perin, Paolo
Gruden, Gabriella
Lorenzati, Bartolomeo
Trovati, Mariella
Di Martino, Leonardo
Mazzaglia, Fabio
Zerbini, Giampaolo
Martina, Valentina
Maestroni, Silvia
Capuano, Valentina
Palmieri, Eva
Lunati, Elena
Grancini, Valeria
Resi, Veronica
Pontiroli, Antonio
Veronelli, Annamaria
Zecchini, Barbara
Arosio, Maura
Montefusco, Laura
Rossi, Antonio
Adda, Guido
Corsi, Anna
Albizzi, Mascia
Zoppini, Giacomo
Avogaro, Angelo
Pucci, Laura
Lucchesi, Daniela
Russo, Eleonora
Garofolo, Monia
Dotta, Francesco
Nigi, Laura
Morano, Susanna
Filardi, Tiziana
Turinese, Irene
Rossetti, Marco
Buzzetti, Raffaella
Foffi, Chiara
Cignarelli, Mauro
Pinnelli, Sabina
Monaco, Lucia
Giorgino, Francesco
Natalicchio, Annalisa
Sesti, Giorgio
Andreozzi, Francesco
Baroni, Marco Giorgio
Frau, Giuseppina
Boi, Alessandra
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00715481 at ClinicalTrials.govDocuments that mention this clinical trial
Independent association of atherogenic dyslipidaemia with all‐cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study
https://doi.org/10.1186/s12933-021-01224-7
Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1007/s00592-018-1133-z
Risk of all-cause mortality according to the European Society of Cardiology risk categories in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1007/s00592-022-01942-8
Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study
https://doi.org/10.1136/bmjdrc-2020-001481
Prognostic impact of switching to the 2021 chronic kidney disease epidemiology collaboration creatinine-based equation in Caucasian patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular events (RIACE) Italian Multicenter Study
https://doi.org/10.1186/s12933-024-02450-5
Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1371/journal.pone.0125512
Body mass index versus surrogate measures of central adiposity as independent predictors of mortality in type 2 diabetes
https://doi.org/10.1186/s12933-022-01706-2
-
Funding
Funding for this research was provided by:
Fondazione Diabete Ricerca
Diabetes, Endocrinology and Metabolism Foundation
Eli Lilly and Company
Sigma-Tau Pharmaceuticals
Boehringer Ingelheim
Chiesi Farmaceutici
Takeda Pharmaceutical Company
- License Information
-
More Information
Article History
Received: 6 June 2022
Accepted: 22 November 2022
First Online: 2 December 2022
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki. The research protocol was approved by the ethics committee of the coordinating centre (Sant’Andrea Hospital, Rome, Italy) on 25 September 2006 (number 43/2006) and subsequently by the ethics committee of each participating centre. Participants provided an informed consent.
: Not applicable.
: EO: consultant fees from Eli Lilly and Novo Nordisk, and lecture fees from Astellas. AS: consultant fees from Axxam, Bayer, and Novo Nordisk, and lecture fees from Eli Lilly, Novo Nordisk, and Sanofi-Aventis. Giuseppe Penno: consultant fees from Bayer and Eli Lilly, and lecture fees from AstraZeneca, Boerhinger Ingelheim, Eli-Lilly, Merck Sharp & Dohme, Mundipharma, Novo Nordisk, and Takeda. EB: consultant fees from Abbott, Bayer, Becton Dickinson, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, and Novo Nordisk. CF: lecture fees from Abbot, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Mundipharma, and Theras Lifetech. RT: consultant fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi-Aventis, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. MV: lecture fees from Lifescan and Novo Nordisk. FC: consultant fees from Boehringer Ingelheim, and lecture fees from AstraZeneca. OL: lecture fees from Eli-Lilly, and grant support from Merck Serono and Merck Sharp & Dohme. JH: lecture fees from Boehringer Ingelheim. AN: consultant fees from AstraZeneca, lecture fees from Eli Lilly, Medtronic, and Novo Nordisk, and grant support from AlfaSigma, Novo Nordisk, Pikdare, Sanofi, Shionogi, SOBI, and Theras. GP: consultant fees from Abbot, Bayer, and Novo Nordisk, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. No other disclosures were reported.
